Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

Anne Kirstine Hundahl Møller; Karen Damgaard Pedersen; Julie Rafn Abildgaard; Bodil Laub Petersen; Gedske Daugaard

doi:10.3109/02841861003649240

Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Julie Rafn Abildgaard, Bodil Laub Petersen, Gedske Daugaard

8 Citationer (Scopus)

Abstract

Background. Treatment of patients with carcinoma of unknown primary site (CUP) remains a challenge, and no effective second-line treatment has been identified. In CUP patients who are non-responsive or relapse early after first-line platinum/taxane-based regimens, it is likely that gastrointestinal (GI) tract tumours may be overrepresented. These patients could be candidates for GI tract-directed therapy. We here report the results obtained with oxaliplatin and capecitabine as second-line therapy in 25 recurrent/refractory CUP patients following first-line treatment with paclitaxel, cisplatin and gemcitabine. Patients and methods. Patients received capecitabine orally (1000 mg/m²) twice daily, days 114, and oxaliplatin (130 mg/m²) intravenously on day 1 in a three-week schedule. Results. Twenty-five CUP patients received a median of three cycles of capecitabine and oxaliplatin as second-line treatment. Histopathological assessments suggested the primary site to be of GI tract origin in the majority of the patients (76%). We found an objective response rate of 13%, a median progression-free survival and overall survival rate of 2.3 and 3.9 months, respectively, and 32% of patients alive at one year after initiation of second-line therapy. The regimen was well tolerated by most patients. Conclusions. This study, demonstrates that there is still a significant need for improved second-line therapy in CUP patients.

Originalsprog	Engelsk
Tidsskrift	Acta Odontologica Scandinavica
Vol/bind	49
Udgave nummer	4
Sider (fra-til)	431-5
Antal sider	5
ISSN	0001-6357
DOI	https://doi.org/10.3109/02841861003649240
Status	Udgivet - 1 maj 2010

Adgang til dokumentet

10.3109/02841861003649240

Citationsformater

@article{98c496a447eb434e886344181ba5ea71,

title = "Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site",

abstract = "Background. Treatment of patients with carcinoma of unknown primary site (CUP) remains a challenge, and no effective second-line treatment has been identified. In CUP patients who are non-responsive or relapse early after first-line platinum/taxane-based regimens, it is likely that gastrointestinal (GI) tract tumours may be overrepresented. These patients could be candidates for GI tract-directed therapy. We here report the results obtained with oxaliplatin and capecitabine as second-line therapy in 25 recurrent/refractory CUP patients following first-line treatment with paclitaxel, cisplatin and gemcitabine. Patients and methods. Patients received capecitabine orally (1000 mg/m2) twice daily, days 114, and oxaliplatin (130 mg/m2) intravenously on day 1 in a three-week schedule. Results. Twenty-five CUP patients received a median of three cycles of capecitabine and oxaliplatin as second-line treatment. Histopathological assessments suggested the primary site to be of GI tract origin in the majority of the patients (76%). We found an objective response rate of 13%, a median progression-free survival and overall survival rate of 2.3 and 3.9 months, respectively, and 32% of patients alive at one year after initiation of second-line therapy. The regimen was well tolerated by most patients. Conclusions. This study, demonstrates that there is still a significant need for improved second-line therapy in CUP patients.",

author = "M{\o}ller, {Anne Kirstine Hundahl} and Pedersen, {Karen Damgaard} and Abildgaard, {Julie Rafn} and Petersen, {Bodil Laub} and Gedske Daugaard",

year = "2010",

month = may,

day = "1",

doi = "10.3109/02841861003649240",

language = "English",

volume = "49",

pages = "431--5",

journal = "Acta Odontologica Scandinavica",

issn = "0001-6357",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

AU - Møller, Anne Kirstine Hundahl

AU - Pedersen, Karen Damgaard

AU - Abildgaard, Julie Rafn

AU - Petersen, Bodil Laub

AU - Daugaard, Gedske

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background. Treatment of patients with carcinoma of unknown primary site (CUP) remains a challenge, and no effective second-line treatment has been identified. In CUP patients who are non-responsive or relapse early after first-line platinum/taxane-based regimens, it is likely that gastrointestinal (GI) tract tumours may be overrepresented. These patients could be candidates for GI tract-directed therapy. We here report the results obtained with oxaliplatin and capecitabine as second-line therapy in 25 recurrent/refractory CUP patients following first-line treatment with paclitaxel, cisplatin and gemcitabine. Patients and methods. Patients received capecitabine orally (1000 mg/m2) twice daily, days 114, and oxaliplatin (130 mg/m2) intravenously on day 1 in a three-week schedule. Results. Twenty-five CUP patients received a median of three cycles of capecitabine and oxaliplatin as second-line treatment. Histopathological assessments suggested the primary site to be of GI tract origin in the majority of the patients (76%). We found an objective response rate of 13%, a median progression-free survival and overall survival rate of 2.3 and 3.9 months, respectively, and 32% of patients alive at one year after initiation of second-line therapy. The regimen was well tolerated by most patients. Conclusions. This study, demonstrates that there is still a significant need for improved second-line therapy in CUP patients.

AB - Background. Treatment of patients with carcinoma of unknown primary site (CUP) remains a challenge, and no effective second-line treatment has been identified. In CUP patients who are non-responsive or relapse early after first-line platinum/taxane-based regimens, it is likely that gastrointestinal (GI) tract tumours may be overrepresented. These patients could be candidates for GI tract-directed therapy. We here report the results obtained with oxaliplatin and capecitabine as second-line therapy in 25 recurrent/refractory CUP patients following first-line treatment with paclitaxel, cisplatin and gemcitabine. Patients and methods. Patients received capecitabine orally (1000 mg/m2) twice daily, days 114, and oxaliplatin (130 mg/m2) intravenously on day 1 in a three-week schedule. Results. Twenty-five CUP patients received a median of three cycles of capecitabine and oxaliplatin as second-line treatment. Histopathological assessments suggested the primary site to be of GI tract origin in the majority of the patients (76%). We found an objective response rate of 13%, a median progression-free survival and overall survival rate of 2.3 and 3.9 months, respectively, and 32% of patients alive at one year after initiation of second-line therapy. The regimen was well tolerated by most patients. Conclusions. This study, demonstrates that there is still a significant need for improved second-line therapy in CUP patients.

U2 - 10.3109/02841861003649240

DO - 10.3109/02841861003649240

M3 - Journal article

SN - 0001-6357

VL - 49

SP - 431

EP - 435

JO - Acta Odontologica Scandinavica

JF - Acta Odontologica Scandinavica

IS - 4

ER -

Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater